United States Patent 11,426,416 (Hypogonadal Male Oral Testosterone Undecanoate Self-Emulsifying System): Claims Scope, Claim-by-Claim Breakdown, and US Patent Landscape
Executive summary: US Patent 11,426,416 claims a twice-daily oral method for treating hypogonadal males using a capsule-encased liquid, where the liquid is a self-emulsifying drug delivery system (SEDDS) containing testosterone undecanoate (TU) plus specified hydrophilic and lipophilic surfactants at defined wt% ranges and a defined lipophilic-to-hydrophilic ratio (about 6:1 to about 3.5:1). The claims tightly constrain (i) TU daily dose (316 to 948 mg TU/day), (ii) steady-state serum testosterone metrics across patient distributions (Cave 300 to 1100 ng/dL in ≥75% of males; Cmax 1800 to 2500 ng/dL in <5%; Cmax ≤1500 ng/dL in ≥85%; and Cmax ≤2500 ng/dL in any male), (iii) optional Tmax (3 to 7 hours), and (iv) optional co-therapies (5-alpha reductase inhibitors; CYP3A4 inhibitor), oil content (10 to 15 wt% digestible oil), and specific surfactant pair (polyoxyethylene(40) hydrogenated castor oil and oleic acid). The practical scope is narrow because it is constrained by specific excipient ratios and by clinical exposure distributions, not only by composition. This narrows easy design-around by simple TU dose changes or generic surfactant substitutions.
What does US Patent 11,426,416 claim: scope of method claims, dose ranges, and exposure distribution limits?
Claim 1 is a “composition-in-capsule + administration + exposure-performance” package
Independent claim 1 defines a method for treating hypogonadal males by orally administering a twice-daily regimen of a specific capsule + liquid formulation. It has multiple tiers of limitations that must all be met:
-
Patient/indication limitation
- “A method for treating a hypogonadal male.”
-
Dosing regimen
- “Orally administering… twice-daily.”
-
Dosage form and unit concept
- The composition is a capsule encasing a liquid formulation.
-
Drug delivery system type
- The liquid formulation is a self-emulsifying drug delivery system (SEDDS).
-
Quantitative formulation composition constraints (wt%)
- TU: 18–22 wt%
- Hydrophilic surfactant: 12–18 wt%
- Lipophilic surfactant: 50–65 wt%
- Surfactant ratio constraint:
- lipophilic surfactant : hydrophilic surfactant about 6:1 to about 3.5:1
- This ratio is a key tightener because it prevents “swapping” one surfactant class for another while keeping total surfactant content similar.
-
Daily TU dose constraint
- “Total TU administered per day ranges from about 316 mg TU to about 948 mg TU.”
-
Steady-state performance constraints at population level
- At steady state, across a plurality of hypogonadal males:
- Cave: 300 to 1100 ng/dL in at least 75% of males
- Cmax distribution:
- Cmax 1800 to 2500 ng/dL in less than 5% of males
- Cmax does not exceed 1500 ng/dL in at least 85% of males
- Cmax does not exceed 2500 ng/dL in any male
Scope consequence: to infringe claim 1, an accused product or method would typically need to satisfy:
- formulation composition bounds (TU wt% and surfactant wt% and ratio),
- dosing schedule and TU mg/day window,
- and the method yields the claimed distribution of serum testosterone exposure metrics at steady state in a clinical cohort.
This creates a high evidentiary burden for challengers and a high relevance of clinical PK data during enforcement or validity challenges.
Which additional limitations narrow infringement under dependent claims 2–9?
Claim 2: Tmax window
- Adds: “serum Tmax at 3 to 7 hours.”
Effect: even within the claim 1 composition/dose/exposure distribution, this further narrows products with substantially different absorption kinetics.
Claim 3: proportionality between Cave and administered TU amount
- Adds: “Cave… is proportional to the amount of TU orally administered.”
Effect: this is another functional PK constraint. It blocks scenarios where TU exposure does not scale predictably with mg/day in the expected way.
Claim 4: optional 5-alpha reductase inhibitor co-therapy
- Adds: formulation further comprises a 5-alpha reductase inhibitor.
Effect: narrows to combination dosing if the inhibitor is included in the formulation being administered. It may also affect infringement theories depending on whether the inhibitor must be co-formulated in the same composition.
Claim 5: optional CYP3A4 inhibitor co-therapy
- Adds: formulation further comprises a CYP3A4 inhibitor.
Effect: narrows to additional drug-inclusion scenarios.
Claim 6: optional digestible oil
- Adds: formulation further comprises a digestible oil.
Claim 7: digestible oil content
- Adds: digestible oil comprises 10–15 wt% of the formulation.
Claim 8: specific surfactant pair
- Adds:
- hydrophilic surfactant is polyoxyethylene(40) hydrogenated castor oil (e.g., Solutol-like class)
- lipophilic surfactant is oleic acid
Effect: claim 8 is a very specific implementation. Even if claim 1 is broader on surfactant identity (only wt% and ratio), claim 8 is enforceable only for that specific pair.
Claim 9: in vitro release profile in fed-state simulated intestinal fluid
- Adds a release behavior:
- “releases about 40 wt% TU within the first 30 minutes and about 60 wt% TU after 4 hours”
- tested in Fed State Simulated Intestinal Fluid medium with specified components and pH 5.
Effect: claim 9 adds a product-performance test constraint that can be used both for enforcement and for invalidity arguments (if prior art has similar release).
Net narrowing pattern: Claims 2–3 add PK timing and proportionality. Claims 4–5 cover combination therapy. Claims 6–7 and 9 add specific composition and release behavior. Claim 8 locks surfactants by identity.
How broad is the formulation coverage: identity vs ratio-based claim structure?
What is claimed about surfactants and oils
- For claim 1, the surfactant constraints are expressed as:
- hydrophilic vs lipophilic categories
- wt% ranges for each
- a lipophilic-to-hydrophilic ratio constraint
- Only in claim 8 do specific surfactants appear by name.
- Oil is optional and constrained only in claims 6–7.
Design-around implications
-
Surfactant identity substitution
- If an accused formulation uses different hydrophilic and lipophilic surfactants but still lands in the same wt% and ratio bands, it may still fall under claim 1.
- If the accused formulation changes the ratio outside “about 6:1 to about 3.5:1,” it may avoid claim 1 even if TU mg/day and PK targets match.
-
TU wt% and daily mg
- Claim 1’s TU wt% (18–22) and daily mg range (316–948 mg TU/day) are both binding. Moving outside either may avoid infringement.
-
Exposures and distribution targets
- The claimed distributions (Cave/Cmax percentages) are hard to “predict” without clinical bridging and can create practical non-infringement positions for generics if clinical PK differs.
-
Performance tests
- Claim 9’s in vitro release profile can enable enforcement against specific manufacturing lots and can also drive validity analysis if prior art already reports similar fed-state release.
Related patent landscape: what other US patents usually matter for oral testosterone undecanoate SEDDS (and why 11,426,416’s claim architecture is distinctive)?
Key adjacent patent families in oral TU
In this therapeutic and formulation space, US patent estates typically cluster into:
- composition/formulation patents for oral TU delivery systems (including SEDDS/SMEDDS)
- capsule-in-capsule or capsule-encased liquid delivery approaches
- surfactant/co-solvent systems and ratio-based excipient designs
- process patents for preparing the emulsion concentrates and filling/encapsulation
- method-of-treatment patents with dosing regimens and PK targets
- combination therapy patents (5-alpha reductase inhibitor; CYP3A4 inhibitors)
Why this patent is different: US 11,426,416 adds a performance layer: it does not only define a formulation; it defines clinically measured steady-state exposure distribution constraints. Many older oral TU patents emphasize composition and bioavailability, but this claim uses distribution thresholds tied to Cave and Cmax proportions across subjects.
Practical infringement testing
- Enforcement typically will demand:
- formulation composition confirmation (TU wt%, surfactant wt%, ratio, digestible oil wt% if relevant),
- dosing schedule confirmation (twice-daily),
- TU mg/day confirmation,
- and clinical PK analysis showing the percentage-based Cmax/Cave limits.
This shifts the dispute toward analytical and clinical evidence.
What is the US litigation and Orange Book relevance for US 11,426,416?
No complete, citation-grade landscape can be produced from the information provided. A correct analysis of:
- whether US 11,426,416 is listed in the FDA Orange Book,
- which NDA/ANDA it maps to,
- whether Paragraph IV challenges exist,
- what litigations or settlements reference it,
- and which generic or capsule/SEDDS entrants are at risk
requires reliable, record-level identifiers (Orange Book drug/product mapping; docket-level litigation references). With only the claim text, those mappings cannot be stated without risk of inaccuracies.
Claim-by-claim risk model for a competitor designing an oral TU SEDDS method
Below is a “constraint satisfaction” model built directly from claim language. It is intended to help identify which levers would most likely avoid infringement.
Core infringement gates under claim 1
An accused method would need to meet all of the following:
- twice-daily oral administration of a capsule-encased liquid
- TU-containing SEDDS with:
- TU wt% 18–22
- hydrophilic surfactant 12–18
- lipophilic surfactant 50–65
- lipophilic-to-hydrophilic ratio about 6:1 to about 3.5:1
- total daily TU dose 316–948 mg/day
- at steady state:
- Cave 300–1100 ng/dL in ≥75% of males
- Cmax 1800–2500 ng/dL in <5% of males
- Cmax ≤1500 ng/dL in ≥85% of males
- Cmax ≤2500 ng/dL in any male
Additional gates under dependent claims
- Claim 2: Tmax 3–7 hours
- Claim 3: Cave proportional to administered TU amount
- Claim 4: formulation includes 5-alpha reductase inhibitor
- Claim 5: formulation includes CYP3A4 inhibitor
- Claim 6–7: digestible oil present at 10–15 wt%
- Claim 8: specific surfactants (polyoxyethylene(40) hydrogenated castor oil and oleic acid)
- Claim 9: fed-state simulated intestinal release profile: ~40% in 30 minutes, ~60% at 4 hours (pH 5 matrix composition as specified)
What formulation patents are likely to overlap in prosecution or obviousness analysis?
Common claim themes that may be used in obviousness attacks
Because claim 1 is constrained by:
- SEDDS structure,
- surfactant system wt% and ratio,
- TU dose bands,
- and clinical exposure distributions,
obviousness and enablement challenges in this field commonly combine:
- Prior art SEDDS TU formulations with overlapping TU wt% and surfactant ranges.
- Published PK/Tmax outcomes showing controllable Cmax and Cave with formulation adjustments.
- Prior art on co-formulated digestible oils, oleic acid-type lipophilic components, and hydrophilic castor oil derivatives.
- Method-of-use claims linking oral TU regimens with PK targets.
But a correct “overlap map” between US 11,426,416 and specific earlier US patents requires searching by assignee/inventor/family and linking to the exact formulation and PK dataset.
Key Takeaways
- Scope is formulation- and performance-defined. US 11,426,416 claim 1 requires meeting TU wt% and surfactant wt% plus a lipophilic/hydrophilic ratio window, a twice-daily dosing regimen, a daily TU mg range, and specific population distribution limits for steady-state Cave and Cmax.
- Dependent claims add further PK and composition constraints. Tmax (3–7 hours), proportionality of Cave to dose, digestible oil content, and a specific surfactant pair (polyoxyethylene(40) hydrogenated castor oil + oleic acid) narrow coverage further.
- Design-around likely hinges on ratio and/or clinical distribution outcomes. Staying within TU mg/day and avoiding the ratio window, or shifting PK distributions outside the claimed percentage thresholds, are the most direct levers.
- A complete US litigation/Orange Book/expiration landscape cannot be asserted from claim text alone.
FAQs
1) Does claim 1 require the exact surfactant identities used in claim 8?
No. Claim 1 defines surfactants by hydrophilic vs lipophilic categories and wt% plus a ratio; claim 8 specifies identities.
2) Can a twice-daily TU SEDDS infringe if TU daily dose falls outside 316 to 948 mg/day?
Not under claim 1 as written, because the total TU administered per day is explicitly limited.
3) Is Cmax measured at fed or fasted state in the claim?
The claim language ties to steady-state serum exposure distributions but does not specify fed vs fasted within the excerpt; it uses population distribution thresholds.
4) Do co-therapy components have to be present in the same formulation to meet claims 4 or 5?
Claims 4–5 state the formulation further comprises the listed inhibitors, so they read as co-formulated inclusions.
5) How does claim 9 change the enforcement strategy?
Claim 9 introduces a specific in vitro release profile in a defined fed-state simulated intestinal fluid at pH 5, enabling formulation-level verification tied to performance testing.
References
- US Patent 11,426,416 (claim set provided in prompt).
